Elicio Therapeutics. has filed a patent for formulations of terevalefim, an HGF/SF mimetic, along with methods of preparation and synthesis. The composition includes specific concentrations of terevalefim, polyethylene glycol, polysorbate, and aqueous components. GlobalData’s report on Elicio Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Elicio Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Elicio Therapeutics's grant share as of January 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Formulation of hgf/sf mimetic terevalefim for medical use
A patent application (Publication Number: US20230372299A1) discloses a composition containing terevalefim, polyethylene glycol, polysorbate, and aqueous components. The composition ranges from 6 mg/mL to 10 mg/mL terevalefim, 20% to 60% polyethylene glycol, and 5% to 15% polysorbate. The aqueous components can include phosphate buffered saline or normal saline. The pH of the composition is maintained between 7.5 and 7.9, and it can be stored at various temperatures for up to 6 months. The composition can be administered intravenously to a subject in need, with dosing instructions provided in the patent claims.
Furthermore, the patent application includes methods for preparing the composition, involving combining terevalefim with polysorbate and polyethylene glycol, adding aqueous components, and ensuring homogeneity and pH adjustment. The methods also detail the use of specific compounds and bases in the preparation process. The composition can be stored for extended periods without significant degradation, making it suitable for pharmaceutical applications. The patent application covers various aspects of the composition, including its formulation, storage conditions, administration methods, and preparation techniques, highlighting its potential for use in medical treatments.
To know more about GlobalData’s detailed insights on Elicio Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
